Bluefish gets approval for cholesterol-reducing medicine

Swedish specialty pharma company Bluefish has been granted approval for its cholesterol reducing medicine Simvastatin in the first EU country. Simvastatin is used to reduce blood cholesterol levels and is one of Europe’s biggest sellers. Bluefish has now begun the process of extending the approval to an additional 25 EU countries. Sales for this pharmaceutical on the EU market total over SEK 10 billion.

“We are continuing to build up our product portfolio, and we are proud that we could get so many approvals so quickly for some of the biggest sellers,” says Bluefish CEO Karl Karlsson.

Today Bluefish has fourteen pharmaceuticals that are approved or under registration in the EU. Bluefish pharmaceuticals are manufactured in India, where Bluefish has a wholly-owned subsidiary.

For more information, please contact: Karl Karlsson, CEO, tel +46 8 679 50 70

Bluefish Pharmaceuticals AB is a Swedish specialty pharma company that buys or licenses the rights to manufacture pharmaceuticals, mainly generic products. Low prices are maintained through efficient production and distribution. Bluefish has a wholly-owned subsidiary in Chennai, India focused on product development and production. The company is owned by its founder Karl Karlsson, and a number of funds and private investors.